Here, we report the structural simplification of a lead compound with activity against multiple biological targets for which large ligands may be advantageous, namely acetylcholinesterase (AChE), BACE-1, and the aggregation of β-amyloid peptide (Aβ) and tau protein, developed as a drug candidate against Alzheimer’s disease (AD). This evidence concerns the gene MAPT and Alzheimer disease.